Loading
PDBj
メニューPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

6D4O

Eubacterium eligens beta-glucuronidase bound to an amoxapine-glucuronide conjugate

6D4O の概要
エントリーDOI10.2210/pdb6d4o/pdb
分子名称Beta-glucuronidase, (5aR,9aR)-2-chloro-11-(4-beta-D-glucopyranuronosylpiperazin-1-yl)-5a,6,9,9a-tetrahydrodibenzo[b,f][1,4]oxazepine, CHLORIDE ION, ... (5 entities in total)
機能のキーワードglycosyl hydrolase, hydrolase
由来する生物種[Eubacterium] eligens
タンパク質・核酸の鎖数1
化学式量合計70387.50
構造登録者
Pellock, S.J.,Walton, W.G.,Redinbo, M.R. (登録日: 2018-04-18, 公開日: 2018-07-25, 最終更新日: 2024-03-13)
主引用文献Pellock, S.J.,Creekmore, B.C.,Walton, W.G.,Mehta, N.,Biernat, K.A.,Cesmat, A.P.,Ariyarathna, Y.,Dunn, Z.D.,Li, B.,Jin, J.,James, L.I.,Redinbo, M.R.
Gut Microbial beta-Glucuronidase Inhibition via Catalytic Cycle Interception.
ACS Cent Sci, 4:868-879, 2018
Cited by
PubMed Abstract: Microbial β-glucuronidases (GUSs) cause severe gut toxicities that limit the efficacy of cancer drugs and other therapeutics. Selective inhibitors of bacterial GUS have been shown to alleviate these side effects. Using structural and chemical biology, mass spectrometry, and cell-based assays, we establish that piperazine-containing GUS inhibitors intercept the glycosyl-enzyme catalytic intermediate of these retaining glycosyl hydrolases. We demonstrate that piperazine-based compounds are substrate-dependent GUS inhibitors that bind to the GUS-GlcA catalytic intermediate as a piperazine-linked glucuronide (GlcA, glucuronic acid). We confirm the GUS-dependent formation of inhibitor-glucuronide conjugates by LC-MS and show that methylated piperazine analogs display significantly reduced potencies. We further demonstrate that a range of approved piperazine- and piperidine-containing drugs from many classes, including those for the treatment of depression, infection, and cancer, function by the same mechanism, and we confirm through gene editing that these compounds selectively inhibit GUS in living bacterial cells. Together, these data reveal a unique mechanism of GUS inhibition and show that a range of therapeutics may impact GUS activities in the human gut.
PubMed: 30062115
DOI: 10.1021/acscentsci.8b00239
主引用文献が同じPDBエントリー
実験手法
X-RAY DIFFRACTION (2.9 Å)
構造検証レポート
Validation report summary of 6d4o
検証レポート(詳細版)ダウンロードをダウンロード

239492

件を2025-07-30に公開中

PDB statisticsPDBj update infoContact PDBjnumon